S3147 |
Entacapone
|
Entacapone (OR-611) inhibits catechol-O-methyltransferase(COMT) with IC50 of 151 nM. Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders. |
-
bioRxiv, 2021, 10.1101/2021.03.22.436393
|
|
S4021 |
Tolcapone
|
Tolcapone (Ro 40-7592) is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with Ki of 30 nM. |
-
Viruses, 2021, 13(8)1533
|
|
S4589 |
Amodiaquine dihydrochloride dihydrate
|
Amodiaquine is a potent, non-competitive inhibitor of histamine N-methyl transferase with estimated Ki of 18.6 nM. It is also used as an antimalarial and anti-inflammatory agent. |
-
Nat Biomed Eng, 2021, 10.1038/s41551-021-00718-9
-
J Med Chem, 2020, 31
-
bioRxiv, 2020, 10.1101/2020.04.13.039917
|
|
S5445 |
AMI-1 (free acid)
|
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively. |
|
|
S7004 |
EPZ005687
|
EPZ005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM in a cell-free assay, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases. |
-
Cancer Cell, 2021, 39(3):407-422.e13
-
Cancer Biol Ther, 2021, 22(4):333-344
-
Nat Commun, 2020, 11(1):604
|
|
S7020 |
UNC0646
|
UNC0646 is a selective histone lysine methyltransferase (HMTase) inhibitor for G9a and GLP with IC50 of 6 nM and 15 nM , respectively, with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity.
|
|
|
S7061 |
GSK126
|
GSK126 (GSK2816126A, GSK2816126) is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, >1000-fold selective for EZH2 over 20 other human methyltransferases. |
-
Nat Cell Biol, 2022, 24(3):384-399
-
Nat Commun, 2022, 13(1):12
-
Cancer Metab, 2022, 10(1):4
|
|
S7062 |
Pinometostat (EPZ5676)
|
Pinometostat (EPZ5676) is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with Ki of 80 pM in a cell-free assay, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. Phase 1. |
-
Cancer Discov, 2022, candisc.0646.2021
-
Mol Cell, 2022, 82(6):1140-1155.e11
-
Nat Biotechnol, 2021, 10.1038/s41587-021-00837-3
|
|
S7079 |
SGC 0946
|
SGC 0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC50 of 0.3 nM in a cell-free assay, is inactive against a panel of 12 PMTs and DNMT1. |
-
Cell Res, 2022, 10.1038/s41422-022-00668-0
-
Transpl Int, 2020, 33(2):229-243
-
Cancer Cell, 2019, 36(2):179-193
|
|
S7120 |
3-deazaneplanocin A (DZNeP) HCl
|
3-deazaneplanocin A HCl (DZNeP, NSC 617989), an analog of adenosine, is a competitive inhibitor of S-adenosylhomocysteine hydrolase with Ki of 50 pM in a cell-free assay. |
-
Nature, 2022, 605(7909):315-324
-
Front Immunol, 2022, 13:818070
-
Nat Cell Biol, 2021, 23(4):341-354
|
|
S7128 |
Tazemetostat (EPZ-6438)
|
Tazemetostat (EPZ-6438, E7438) is a potent, and selective EZH2 inhibitor with Ki and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs. |
-
Nat Cell Biol, 2022, 24(3):384-399
-
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
-
Nat Commun, 2022, 13(1):12
|
|
S7164 |
GSK343
|
GSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM in a cell-free assay, showing 60 fold selectivity against EZH1, and >1000 fold selectivity against other histone methyltransferases. GSK343 induces autophagy. |
-
Hepatology, 2022, 10.1002/hep.32443
-
Theranostics, 2022, 12(5):2063-2079
-
J Immunol, 2022, 208(2):347-357
|
|
S7165 |
UNC1999
|
UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. UNC1999 is a potent autophagy inducer. UNC1999 specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis. |
-
Pharmacol Res, 2022, 177:106122
-
J Immunol, 2022, 208(2):347-357
-
Hepatology, 2021, 10.1002/hep.32245
|
|
S7230 |
UNC0642
|
UNC0642 is a potent, selective inhibitor of histone methyltransferases G9a/GLP with IC50s less than 2.5 nM for G9a and GLP and shows more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels. |
-
Cancer Metab, 2022, 10(1):4
-
Blood, 2021, blood.2020009195
-
Blood, 2021, 138(9):790-805
|
|
S7265 |
MM-102
|
MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM in a cell-free assay. |
-
Cell Death Discov, 2022, 8(1):180
-
J Cell Mol Med, 2020, 10.1111/jcmm.16030
-
Mol Carcinog, 2020, 10.1002/mc.23147
|
|
S7294 |
PFI-2 HCl
|
PFI-2 is a potent, selective, and cell-active lysine methyltransferase SETD7 inhibitor with Ki (app) and IC50 of 0.33 nM and 2 nM, 1000-fold selectivity over other methyltransferases and other non-epigenetic targets.
|
-
Pharmacol Res, 2022, 177:106122
-
Brain Behav Immun, 2019, 82:382-395
-
Cancer Res, 2018, 78(20):5731-5740
|
|
S7353 |
EPZ004777
|
EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM in a cell-free assay and demonstrates >1,200-fold selectivity for DOT1L over all other tested PMTs. EPZ004777 induces apoptosis. |
-
Cell Res, 2022, 10.1038/s41422-022-00668-0
-
Proc Natl Acad Sci U S A, 2021, 118(29)e2104013118
-
Nat Chem Biol, 2020, 10.1038/s41589-020-0618-6
|
|
S7570 |
UNC0379
|
UNC0379 is a selective, substrate competitive inhibitor of N-lysine methyltransferase SETD8 with IC50 of 7.9 μM, high selectivity over 15 other methyltransferases. |
-
Acta Biochim Biophys Sin (Shanghai), 2021, gmab140
-
J Biol Chem, 2020, 10.1074/jbc.RA119.010951
-
Biochim Biophys Acta Gene Regul Mech, 2019, 1862(2):173-183
|
|
S7572 |
A-366
|
A-366 is a potent and selective G9a/GLP histone lysine methyltransferase inhibitor with IC50 of 3.3nM, exhibiting >1000-fold selectivity for G9a/GLP over 21 other methyltransferases. |
-
Pharmacol Res, 2022, 177:106122
-
Nat Med, 2019, 25(7):1073-1081
-
Genome Res, 2019, 29(10):1659-1672
|
|
S7575 |
LLY-507
|
LLY-507 is a cell-active, potent, and selective inhibitor of protein-lysine Methyltransferase SMYD2. |
-
Pharmacol Res, 2022, 177:106122
-
Oncol Lett, 2020, 20(5):153
-
J Immunother Cancer, 2019, 7(1):277
|
|
S7591 |
BRD4770
|
BRD4770 is a histone methyltransferase G9a inhibitor with IC50 of 6.3 μM, and induces cell senescence.
|
-
Pharmacol Res, 2022, 177:106122
-
Cancer Res, 2018, 78(20):5731-5740
-
Hum Pathol, 2018, 72:117-126
|
|
S7611 |
EI1
|
EI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
|
-
Cancer Res, 2018, 78(20):5731-5740
-
Mol Cancer, 2017, 10.1186/s12943-016-0575-6
-
Virology, 2017, 506:34-44
|
|
S7616 |
CPI-169
|
CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively. |
-
Cell Chem Biol, 2021, S2451-9456(21)00213-0
-
Cancer Sci, 2020, 112(1):133-143
-
J Clin Invest, 2020, 134217
|
|
S7618 |
MI-2 (Menin-MLL Inhibitor)
|
MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.
|
-
Life Sci Alliance, 2022, 5(4)e202101187
-
J Immunol, 2021, ji1901348
-
Cell Rep, 2019, 26(2):415-428
|
|
S7619 |
MI-3 (Menin-MLL Inhibitor)
|
MI-3 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 648 nM.
|
-
Nature, 2021, 10.1038/s41586-021-04116-8
-
Clin Epigenetics, 2019, 11(1):137
-
Cancer Res, 2018, 78(20):5731-5740
|
|
S7656 |
CPI-360
|
CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.
|
-
Cancer Res, 2018, 78(20):5731-5740
|
|
S7748 |
EPZ015666 (GSK3235025)
|
EPZ015666 (GSK3235025) is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs.
|
-
Sci Adv, 2021, 7(13)eabc1834
-
Front Immunol, 2021, 12:695947
-
Ann Transl Med, 2021, 9(9):755
|
|
S7804 |
GSK503
|
GSK503 is a potent and specific EZH2 methyltransferase inhibitor.
|
-
Cancer Cell, 2019, 36(4):385-401
-
Cancer Res, 2018, 78(20):5731-5740
-
J Pathol, 2018, 245(4):433-444
|
|
S7805 |
EPZ011989
|
EPZ011989 is a potent, selective, orally bioavailable EZH2 inhibitor with Ki of <3 nM. |
-
Neuron, 2022, S0896-6273(21)01089-8
-
Mol Neurobiol, 2022, 10.1007/s12035-021-02602-8
-
Mol Cancer Ther, 2021, 20(3):541-552
|
|
S7815 |
MI-136
|
MI-136 can specifically inhibit the menin-MLL interaction. It inhibits DHT-induced expression of androgen receptor (AR) target genes. |
-
J Med Chem, 2020, 31
|
|
S7816 |
MI-463
|
MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM. |
-
Front Oncol, 2020, 10:524922
|
|
S7817 |
MI-503
|
MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. It shows pronounced growth suppressive activity in a panel of human MLL leukemia cell lines(GI50 at 250 nM-570 nM range), but only a minimal effect in human leukemia cell lines without MLL translocations. |
-
J Assoc Res Otolaryngol, 2021, 10.1007/s10162-021-00801-7
-
Johannes Gutenberg-Universität Mainz, 2021, 10.25358/openscience-5949
-
Cancers (Basel), 2020, 12(9)E2715
|
|
S7820New |
EPZ020411 2HCl
|
EPZ020411 is a potent and selective small molecule PRMT6 inhibitor with an IC50 of 10 nM. |
-
Inflamm Res, 2022, 71(3):309-320
-
Theranostics, 2020, 10(1):133-150
|
|
S7832 |
SGC707
|
SGC707 is a potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) with IC50 and Kd of 31 nM and 53 nM, respectively.
|
-
J Med Chem, 2020, 31
-
Transpl Int, 2020, 33(2):229-243
-
J Immunother Cancer, 2019, 7(1):277
|
|
S7868 |
S-Adenosyl-L-homocysteine (SAH)
|
S-Adenosyl-L-homocysteine (SAH, S-Adenosylhomocysteine, AdoHcy, Formycinylhomocysteine) is an inhibitor for (Methyltransferase Like 3-14) METTL3-METTL14 heterodimer complex (METTL3-14) with IC50 of 0.9 μM. |
|
|
S7884 |
AMI-1
|
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.
|
-
Oncogene, 2021, 10.1038/s41388-020-01617-0
-
Oncogene, 2021, 40(7):1375-1389
-
Research Square, 2021, 10.21203/rs.3.rs-620216/v1
|
|
S7983 |
A-196
|
A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 with IC50 values of 0.025 and 0.144 μM, respectively; more than 100-fold selective over other histone methyltransferases and non-epigenetic targets.
|
-
PLoS One, 2021, 16(6):e0252504
-
J Immunother Cancer, 2019, 7(1):277
-
Nucleic Acids Res, 2019, 47(21):10977-10993
|
|
S8006 |
BIX 01294
|
BIX01294 is an inhibitor of G9a histone methyltransferase with IC50 of 2.7 μM in a cell-free assay, reduces H3K9me2 of bulk histones, also weakly inhibits GLP (primarily H3K9me3), no significant activity observed at other histone methyltransferases. BIX01294 induces autophagy. BIX01294 also inhibits H3K36 methylation by oncoproteins NSD1, NSD2 and NSD3. |
-
Pharmacol Res, 2022, 177:106122
-
Int J Mol Sci, 2022, 23(8)4213
-
Adv Sci (Weinh), 2021, e2100779
|
|
S8068 |
Chaetocin
|
Chaetocin, a natural product from Chaetomium species, is a histone methyltransferase inhibitor with IC50 of 0.8 μM, 2.5 μM and 3 μM for dSU(VAR)3-9, mouse G9a and Neurospora crassa DIM5, respectively. Chaetocin is an anticancer agent and inhibitor of thioredoxin reductase (TrxR). |
-
Eye Vis (Lond), 2022, 9(1):4
-
Free Radic Biol Med, 2021, 178:147-160
-
Cancer Discov, 2021, candisc.0872.2020
|
|
S8071 |
UNC0638
|
UNC0638 is a potent, selective and cell-penetrant chemical probe for G9a and GLP histone methyltransferase with IC50 of <15 nM and 19 nM, respectively, shows selectivity over a wide range of epigenetic and non-epigenetic targets. UNC0638 has anti-viral activities. |
-
PLoS Pathog, 2022, 18(5):e1010505
-
Adv Sci (Weinh), 2021, e2100779
-
Sci Adv, 2021, 7(3)eaba8053
|
|
S8111 |
GSK591
|
GSK591 (EPZ015866, GSK3203591) is a potent selective inhibitor of the arginine methyltransferase PRMT5 with IC50 of 4 nM. |
-
Hepatology, 2021, 10.1002/hep.32245
-
Hepatology, 2021, 10.1002/hep.32245
-
Cancer Sci, 2021, 10.1111/cas.14988
|
|
S8112 |
MS023
|
MS023 is a potent, selective, and cell-active Type I PRMT inhibitor with IC50 of 30 nM, 119 nM, 83 nM, 4 nM, and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively.
|
-
Sci Adv, 2022, 8(4):eabi7711
-
Oncogene, 2021, 10.1038/s41388-020-01617-0
-
Oncogene, 2021, 40(7):1375-1389
|
|
S8147 |
MS049
|
MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively. |
-
Research Square, 2021, 10.21203/rs.3.rs-620216/v1
-
EMBO Rep, 2020, 21(2):e48597
|
|
S8209 |
HLCL-61 HCL
|
HLCL-61 hydrochloride is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia. |
-
Nat Commun, 2018, 9(1):1572
-
Cancer Res, 2018, 78(20):5731-5740
|
|
S8340 |
SGC2085
|
SGC2085 is a potent and selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) inhibitor with an IC50 value of 50 nM and >100-fold selective over other PRMTs.
|
|
|
S8353 |
Lirametostat (CPI-1205)
|
Lirametostat (CPI-1205) is an orally available selective inhibitor of the histone lysine methyltransferase EZH2 with IC50 values of 2 nM and 52 nM for EZH2 and EZH1 respectively. It has potential antineoplastic activity. |
-
Nat Commun, 2021, 12(1):6276
-
J Immunother Cancer, 2021, 9(5)e001335
-
Cancer Discov, 2021, candisc.0913.2020
|
|
S8494 |
PF-06726304
|
PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively; also inhibits H3K27me3 with the IC50 value of 15 nM.
|
-
Elife, 2021, 10e65654
|
|
S8607 |
JQ-EZ-05 (JQEZ5)
|
JQ-EZ-05 (JQEZ5) is a specific and reversible EZH1/2 inhibitor. |
-
Nat Chem Biol, 2019, 15(4):391-400
|
|
S8624 |
Onametostat (JNJ-64619178)
|
Onametostat (JNJ-64619178) is a PRMT5 inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under different in vitro and cellular conditions, paired with favorable pharmacokinetics and safety properties.
|
-
Proc Natl Acad Sci U S A, 2021, 118(34)e2024055118
|
|
S8664 |
Pemrametostat (GSK3326595)
|
Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models. |
-
Sci Adv, 2021, 7(13)eabc1834
-
Proc Natl Acad Sci U S A, 2021, 118(34)e2024055118
-
Cell Chem Biol, 2021, S2451-9456(21)00400-1
|
|
S8702 |
EBI-2511
|
EBI-2511 is a highly potent and orally active EZH2 inhibitor with an IC50 of 4 nM for EZH2(A667G). |
|
|
S8918 |
MS1943
|
MS1943 is an orally bioavailable EZH2 selective degrader that effectively reduces EZH2 levels in cells with IC50 of 120 nM for inhibiting EZH2 methyltransferase activity. |
|
|
S8934 |
VTP50469
|
VTP50469 is a potent, highly selective and orally active inhibitor of Menin-MLL interaction with Ki of 104 pM. VTP50469 exhibits anti-leukemia activity. |
|
|
S8983 |
MAK683
|
MAK683 (EED inhibitor-1, example 2) is an inhibitor of embryonic ectoderm development (EED). MAK683 exhibits IC50 of 59 nM, 89 nM and 26 nM in EED Alphascreen binding, LC-MS and ELISA assay, respectively. |
-
Cell Death Dis, 2022, 13(2):155
|
|
S9659 |
UNC6852
|
UNC6852 is a selective degrader that targets polycomb repressive complex 2 (PRC2) with IC50 of 247 nM for EED. UNC6852 is based on PROTAC and contains an EED226-derived ligand and a ligand for VHL. |
|
|
A5058 |
Brd4 Rabbit Recombinant mAb
|
Brd4 Rabbit Recombinant mAb detects endogenous levels of total Brd4. |
|
|
A5240 |
ASH2L Rabbit Recombinant mAb
|
ASH2L Rabbit Recombinant mAb detects endogenous level of total ASH2L. |
|
|
A5247 |
PRMT5 Rabbit Recombinant mAb
|
PRMT5 Rabbit Recombinant mAb detects endogenous level of total PRMT5. |
|
|
S2184 |
WDR5-0103
|
WDR5-0103 (WD-Repeat Protein 5-0103) is a small-molecule antagonist of WDR5 (WD40 repeat protein 5) with Kd of 450 nM. |
|
|
S7833 |
OICR-9429
|
OICR-9429 is a potent antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3 and reduces viability of acute myeloid leukemia cells in vitro. It binds to WDR5 with high affinity (KD = 93 ± 28 nM. |
-
iScience, 2022, 25(1):103679
-
Nature, 2021, 10.1038/s41586-021-04116-8
-
J Exp Clin Cancer Res, 2021, 40(1):203
|
|
S8359 |
UNC3866
|
UNC3866 is a potent antagonist of the methyllysine (Kme) reading function of the Polycomb CBX and CDY families of chromodomains. UNC3866 binds the chromodomains of CBX4 and CBX7 most potently, with a K(d) of ∼100 nM for each, and is 6- to 18-fold selective as compared to seven other CBX and CDY chromodomains. |
-
Leukemia, 2021, 10.1038/s41375-021-01121-8
-
Int J Mol Sci, 2021, 22(2)E619
-
Leukemia, 2021, 10.1038/s41375-021-01121-8
|
|
S8496 |
EED226
|
EED226 is a potent, selective, and orally bioavailable a novel allosteric Polycomb repressive complex 2 (PRC2) inhibitor with an IC50 of 23.4 nM when the H3K27me0 peptide was used as substrate and an IC50 of 53.5 nM when the mononucleosome was used as the substrate. It directly binds to the H3K27me3 binding pocket of EED. |
-
Cell Death Dis, 2022, 13(2):155
-
Mol Cell, 2021, 81(10):2183-2200.e13
-
Nat Commun, 2021, 12(1):6985
|
|
S3147 |
Entacapone
|
Entacapone (OR-611) inhibits catechol-O-methyltransferase(COMT) with IC50 of 151 nM. Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders. |
- bioRxiv, 2021, 10.1101/2021.03.22.436393
|
|
S4021 |
Tolcapone
|
Tolcapone (Ro 40-7592) is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with Ki of 30 nM. |
- Viruses, 2021, 13(8)1533
|
|
S4589 |
Amodiaquine dihydrochloride dihydrate
|
Amodiaquine is a potent, non-competitive inhibitor of histamine N-methyl transferase with estimated Ki of 18.6 nM. It is also used as an antimalarial and anti-inflammatory agent. |
- Nat Biomed Eng, 2021, 10.1038/s41551-021-00718-9
- J Med Chem, 2020, 31
- bioRxiv, 2020, 10.1101/2020.04.13.039917
|
|
S5445 |
AMI-1 (free acid)
|
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively. |
|
|
S7004 |
EPZ005687
|
EPZ005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM in a cell-free assay, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases. |
- Cancer Cell, 2021, 39(3):407-422.e13
- Cancer Biol Ther, 2021, 22(4):333-344
- Nat Commun, 2020, 11(1):604
|
|
S7020 |
UNC0646
|
UNC0646 is a selective histone lysine methyltransferase (HMTase) inhibitor for G9a and GLP with IC50 of 6 nM and 15 nM , respectively, with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity.
|
|
|
S7061 |
GSK126
|
GSK126 (GSK2816126A, GSK2816126) is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, >1000-fold selective for EZH2 over 20 other human methyltransferases. |
- Nat Cell Biol, 2022, 24(3):384-399
- Nat Commun, 2022, 13(1):12
- Cancer Metab, 2022, 10(1):4
|
|
S7062 |
Pinometostat (EPZ5676)
|
Pinometostat (EPZ5676) is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with Ki of 80 pM in a cell-free assay, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. Phase 1. |
- Cancer Discov, 2022, candisc.0646.2021
- Mol Cell, 2022, 82(6):1140-1155.e11
- Nat Biotechnol, 2021, 10.1038/s41587-021-00837-3
|
|
S7079 |
SGC 0946
|
SGC 0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC50 of 0.3 nM in a cell-free assay, is inactive against a panel of 12 PMTs and DNMT1. |
- Cell Res, 2022, 10.1038/s41422-022-00668-0
- Transpl Int, 2020, 33(2):229-243
- Cancer Cell, 2019, 36(2):179-193
|
|
S7120 |
3-deazaneplanocin A (DZNeP) HCl
|
3-deazaneplanocin A HCl (DZNeP, NSC 617989), an analog of adenosine, is a competitive inhibitor of S-adenosylhomocysteine hydrolase with Ki of 50 pM in a cell-free assay. |
- Nature, 2022, 605(7909):315-324
- Front Immunol, 2022, 13:818070
- Nat Cell Biol, 2021, 23(4):341-354
|
|
S7128 |
Tazemetostat (EPZ-6438)
|
Tazemetostat (EPZ-6438, E7438) is a potent, and selective EZH2 inhibitor with Ki and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs. |
- Nat Cell Biol, 2022, 24(3):384-399
- Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
- Nat Commun, 2022, 13(1):12
|
|
S7164 |
GSK343
|
GSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM in a cell-free assay, showing 60 fold selectivity against EZH1, and >1000 fold selectivity against other histone methyltransferases. GSK343 induces autophagy. |
- Hepatology, 2022, 10.1002/hep.32443
- Theranostics, 2022, 12(5):2063-2079
- J Immunol, 2022, 208(2):347-357
|
|
S7165 |
UNC1999
|
UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. UNC1999 is a potent autophagy inducer. UNC1999 specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis. |
- Pharmacol Res, 2022, 177:106122
- J Immunol, 2022, 208(2):347-357
- Hepatology, 2021, 10.1002/hep.32245
|
|
S7230 |
UNC0642
|
UNC0642 is a potent, selective inhibitor of histone methyltransferases G9a/GLP with IC50s less than 2.5 nM for G9a and GLP and shows more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels. |
- Cancer Metab, 2022, 10(1):4
- Blood, 2021, blood.2020009195
- Blood, 2021, 138(9):790-805
|
|
S7265 |
MM-102
|
MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM in a cell-free assay. |
- Cell Death Discov, 2022, 8(1):180
- J Cell Mol Med, 2020, 10.1111/jcmm.16030
- Mol Carcinog, 2020, 10.1002/mc.23147
|
|
S7294 |
PFI-2 HCl
|
PFI-2 is a potent, selective, and cell-active lysine methyltransferase SETD7 inhibitor with Ki (app) and IC50 of 0.33 nM and 2 nM, 1000-fold selectivity over other methyltransferases and other non-epigenetic targets.
|
- Pharmacol Res, 2022, 177:106122
- Brain Behav Immun, 2019, 82:382-395
- Cancer Res, 2018, 78(20):5731-5740
|
|
S7353 |
EPZ004777
|
EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM in a cell-free assay and demonstrates >1,200-fold selectivity for DOT1L over all other tested PMTs. EPZ004777 induces apoptosis. |
- Cell Res, 2022, 10.1038/s41422-022-00668-0
- Proc Natl Acad Sci U S A, 2021, 118(29)e2104013118
- Nat Chem Biol, 2020, 10.1038/s41589-020-0618-6
|
|
S7570 |
UNC0379
|
UNC0379 is a selective, substrate competitive inhibitor of N-lysine methyltransferase SETD8 with IC50 of 7.9 μM, high selectivity over 15 other methyltransferases. |
- Acta Biochim Biophys Sin (Shanghai), 2021, gmab140
- J Biol Chem, 2020, 10.1074/jbc.RA119.010951
- Biochim Biophys Acta Gene Regul Mech, 2019, 1862(2):173-183
|
|
S7572 |
A-366
|
A-366 is a potent and selective G9a/GLP histone lysine methyltransferase inhibitor with IC50 of 3.3nM, exhibiting >1000-fold selectivity for G9a/GLP over 21 other methyltransferases. |
- Pharmacol Res, 2022, 177:106122
- Nat Med, 2019, 25(7):1073-1081
- Genome Res, 2019, 29(10):1659-1672
|
|
S7575 |
LLY-507
|
LLY-507 is a cell-active, potent, and selective inhibitor of protein-lysine Methyltransferase SMYD2. |
- Pharmacol Res, 2022, 177:106122
- Oncol Lett, 2020, 20(5):153
- J Immunother Cancer, 2019, 7(1):277
|
|
S7591 |
BRD4770
|
BRD4770 is a histone methyltransferase G9a inhibitor with IC50 of 6.3 μM, and induces cell senescence.
|
- Pharmacol Res, 2022, 177:106122
- Cancer Res, 2018, 78(20):5731-5740
- Hum Pathol, 2018, 72:117-126
|
|
S7611 |
EI1
|
EI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
|
- Cancer Res, 2018, 78(20):5731-5740
- Mol Cancer, 2017, 10.1186/s12943-016-0575-6
- Virology, 2017, 506:34-44
|
|
S7616 |
CPI-169
|
CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively. |
- Cell Chem Biol, 2021, S2451-9456(21)00213-0
- Cancer Sci, 2020, 112(1):133-143
- J Clin Invest, 2020, 134217
|
|
S7618 |
MI-2 (Menin-MLL Inhibitor)
|
MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.
|
- Life Sci Alliance, 2022, 5(4)e202101187
- J Immunol, 2021, ji1901348
- Cell Rep, 2019, 26(2):415-428
|
|
S7619 |
MI-3 (Menin-MLL Inhibitor)
|
MI-3 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 648 nM.
|
- Nature, 2021, 10.1038/s41586-021-04116-8
- Clin Epigenetics, 2019, 11(1):137
- Cancer Res, 2018, 78(20):5731-5740
|
|
S7656 |
CPI-360
|
CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.
|
- Cancer Res, 2018, 78(20):5731-5740
|
|
S7748 |
EPZ015666 (GSK3235025)
|
EPZ015666 (GSK3235025) is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs.
|
- Sci Adv, 2021, 7(13)eabc1834
- Front Immunol, 2021, 12:695947
- Ann Transl Med, 2021, 9(9):755
|
|
S7804 |
GSK503
|
GSK503 is a potent and specific EZH2 methyltransferase inhibitor.
|
- Cancer Cell, 2019, 36(4):385-401
- Cancer Res, 2018, 78(20):5731-5740
- J Pathol, 2018, 245(4):433-444
|
|
S7805 |
EPZ011989
|
EPZ011989 is a potent, selective, orally bioavailable EZH2 inhibitor with Ki of <3 nM. |
- Neuron, 2022, S0896-6273(21)01089-8
- Mol Neurobiol, 2022, 10.1007/s12035-021-02602-8
- Mol Cancer Ther, 2021, 20(3):541-552
|
|
S7815 |
MI-136
|
MI-136 can specifically inhibit the menin-MLL interaction. It inhibits DHT-induced expression of androgen receptor (AR) target genes. |
- J Med Chem, 2020, 31
|
|
S7816 |
MI-463
|
MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM. |
- Front Oncol, 2020, 10:524922
|
|
S7817 |
MI-503
|
MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. It shows pronounced growth suppressive activity in a panel of human MLL leukemia cell lines(GI50 at 250 nM-570 nM range), but only a minimal effect in human leukemia cell lines without MLL translocations. |
- J Assoc Res Otolaryngol, 2021, 10.1007/s10162-021-00801-7
- Johannes Gutenberg-Universität Mainz, 2021, 10.25358/openscience-5949
- Cancers (Basel), 2020, 12(9)E2715
|
|
S7820New |
EPZ020411 2HCl
|
EPZ020411 is a potent and selective small molecule PRMT6 inhibitor with an IC50 of 10 nM. |
- Inflamm Res, 2022, 71(3):309-320
- Theranostics, 2020, 10(1):133-150
|
|
S7832 |
SGC707
|
SGC707 is a potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) with IC50 and Kd of 31 nM and 53 nM, respectively.
|
- J Med Chem, 2020, 31
- Transpl Int, 2020, 33(2):229-243
- J Immunother Cancer, 2019, 7(1):277
|
|
S7868 |
S-Adenosyl-L-homocysteine (SAH)
|
S-Adenosyl-L-homocysteine (SAH, S-Adenosylhomocysteine, AdoHcy, Formycinylhomocysteine) is an inhibitor for (Methyltransferase Like 3-14) METTL3-METTL14 heterodimer complex (METTL3-14) with IC50 of 0.9 μM. |
|
|
S7884 |
AMI-1
|
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.
|
- Oncogene, 2021, 10.1038/s41388-020-01617-0
- Oncogene, 2021, 40(7):1375-1389
- Research Square, 2021, 10.21203/rs.3.rs-620216/v1
|
|
S7983 |
A-196
|
A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 with IC50 values of 0.025 and 0.144 μM, respectively; more than 100-fold selective over other histone methyltransferases and non-epigenetic targets.
|
- PLoS One, 2021, 16(6):e0252504
- J Immunother Cancer, 2019, 7(1):277
- Nucleic Acids Res, 2019, 47(21):10977-10993
|
|
S8006 |
BIX 01294
|
BIX01294 is an inhibitor of G9a histone methyltransferase with IC50 of 2.7 μM in a cell-free assay, reduces H3K9me2 of bulk histones, also weakly inhibits GLP (primarily H3K9me3), no significant activity observed at other histone methyltransferases. BIX01294 induces autophagy. BIX01294 also inhibits H3K36 methylation by oncoproteins NSD1, NSD2 and NSD3. |
- Pharmacol Res, 2022, 177:106122
- Int J Mol Sci, 2022, 23(8)4213
- Adv Sci (Weinh), 2021, e2100779
|
|
S8068 |
Chaetocin
|
Chaetocin, a natural product from Chaetomium species, is a histone methyltransferase inhibitor with IC50 of 0.8 μM, 2.5 μM and 3 μM for dSU(VAR)3-9, mouse G9a and Neurospora crassa DIM5, respectively. Chaetocin is an anticancer agent and inhibitor of thioredoxin reductase (TrxR). |
- Eye Vis (Lond), 2022, 9(1):4
- Free Radic Biol Med, 2021, 178:147-160
- Cancer Discov, 2021, candisc.0872.2020
|
|
S8071 |
UNC0638
|
UNC0638 is a potent, selective and cell-penetrant chemical probe for G9a and GLP histone methyltransferase with IC50 of <15 nM and 19 nM, respectively, shows selectivity over a wide range of epigenetic and non-epigenetic targets. UNC0638 has anti-viral activities. |
- PLoS Pathog, 2022, 18(5):e1010505
- Adv Sci (Weinh), 2021, e2100779
- Sci Adv, 2021, 7(3)eaba8053
|
|
S8111 |
GSK591
|
GSK591 (EPZ015866, GSK3203591) is a potent selective inhibitor of the arginine methyltransferase PRMT5 with IC50 of 4 nM. |
- Hepatology, 2021, 10.1002/hep.32245
- Hepatology, 2021, 10.1002/hep.32245
- Cancer Sci, 2021, 10.1111/cas.14988
|
|
S8112 |
MS023
|
MS023 is a potent, selective, and cell-active Type I PRMT inhibitor with IC50 of 30 nM, 119 nM, 83 nM, 4 nM, and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively.
|
- Sci Adv, 2022, 8(4):eabi7711
- Oncogene, 2021, 10.1038/s41388-020-01617-0
- Oncogene, 2021, 40(7):1375-1389
|
|
S8147 |
MS049
|
MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively. |
- Research Square, 2021, 10.21203/rs.3.rs-620216/v1
- EMBO Rep, 2020, 21(2):e48597
|
|
S8209 |
HLCL-61 HCL
|
HLCL-61 hydrochloride is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia. |
- Nat Commun, 2018, 9(1):1572
- Cancer Res, 2018, 78(20):5731-5740
|
|
S8340 |
SGC2085
|
SGC2085 is a potent and selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) inhibitor with an IC50 value of 50 nM and >100-fold selective over other PRMTs.
|
|
|
S8353 |
Lirametostat (CPI-1205)
|
Lirametostat (CPI-1205) is an orally available selective inhibitor of the histone lysine methyltransferase EZH2 with IC50 values of 2 nM and 52 nM for EZH2 and EZH1 respectively. It has potential antineoplastic activity. |
- Nat Commun, 2021, 12(1):6276
- J Immunother Cancer, 2021, 9(5)e001335
- Cancer Discov, 2021, candisc.0913.2020
|
|
S8494 |
PF-06726304
|
PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively; also inhibits H3K27me3 with the IC50 value of 15 nM.
|
- Elife, 2021, 10e65654
|
|
S8607 |
JQ-EZ-05 (JQEZ5)
|
JQ-EZ-05 (JQEZ5) is a specific and reversible EZH1/2 inhibitor. |
- Nat Chem Biol, 2019, 15(4):391-400
|
|
S8624 |
Onametostat (JNJ-64619178)
|
Onametostat (JNJ-64619178) is a PRMT5 inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under different in vitro and cellular conditions, paired with favorable pharmacokinetics and safety properties.
|
- Proc Natl Acad Sci U S A, 2021, 118(34)e2024055118
|
|
S8664 |
Pemrametostat (GSK3326595)
|
Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models. |
- Sci Adv, 2021, 7(13)eabc1834
- Proc Natl Acad Sci U S A, 2021, 118(34)e2024055118
- Cell Chem Biol, 2021, S2451-9456(21)00400-1
|
|
S8702 |
EBI-2511
|
EBI-2511 is a highly potent and orally active EZH2 inhibitor with an IC50 of 4 nM for EZH2(A667G). |
|
|
S8918 |
MS1943
|
MS1943 is an orally bioavailable EZH2 selective degrader that effectively reduces EZH2 levels in cells with IC50 of 120 nM for inhibiting EZH2 methyltransferase activity. |
|
|
S8934 |
VTP50469
|
VTP50469 is a potent, highly selective and orally active inhibitor of Menin-MLL interaction with Ki of 104 pM. VTP50469 exhibits anti-leukemia activity. |
|
|
S8983 |
MAK683
|
MAK683 (EED inhibitor-1, example 2) is an inhibitor of embryonic ectoderm development (EED). MAK683 exhibits IC50 of 59 nM, 89 nM and 26 nM in EED Alphascreen binding, LC-MS and ELISA assay, respectively. |
- Cell Death Dis, 2022, 13(2):155
|
|
S9659 |
UNC6852
|
UNC6852 is a selective degrader that targets polycomb repressive complex 2 (PRC2) with IC50 of 247 nM for EED. UNC6852 is based on PROTAC and contains an EED226-derived ligand and a ligand for VHL. |
|
|